Long-term prevention of hypertension and end-organ damage in Ren-2 transgenic rats is achieved only with persistent but not transient AT1 receptor blockade
Jazyk angličtina Země Švýcarsko Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
17237618
DOI
10.1159/000098869
PII: 000098869
Knihovny.cz E-zdroje
- MeSH
- benzimidazoly farmakologie MeSH
- bifenylové sloučeniny MeSH
- blokátory receptorů AT1 pro angiotensin II farmakologie MeSH
- geneticky modifikovaná zvířata MeSH
- krevní tlak MeSH
- krysa rodu Rattus MeSH
- ledviny patofyziologie MeSH
- potkani Sprague-Dawley MeSH
- proteinurie moč MeSH
- receptor angiotensinu typ 1 metabolismus MeSH
- receptor angiotensinu typ 2 krev metabolismus fyziologie MeSH
- renální hypertenze farmakoterapie MeSH
- renin genetika MeSH
- tetrazoly farmakologie MeSH
- zvířata MeSH
- Check Tag
- krysa rodu Rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- benzimidazoly MeSH
- bifenylové sloučeniny MeSH
- blokátory receptorů AT1 pro angiotensin II MeSH
- candesartan MeSH Prohlížeč
- receptor angiotensinu typ 1 MeSH
- receptor angiotensinu typ 2 MeSH
- Ren2 protein, mouse MeSH Prohlížeč
- renin MeSH
- tetrazoly MeSH
The aim of this study was first to evaluate the effects of persistent or transient blockade of the angiotensin II (ANG II) receptor AT(1) on the development of hypertension and end-organ damage in hypertensive Ren-2 transgenic rats (TGR), and second to assess the potential role of AT(2) receptors in the control of blood pressure (BP) in this monogenetic model of hypertension. Male heterozygous TGR and Hannover Sprague-Dawley (HanSD) rats fed a normal salt diet were treated from day 32 of age either persistently until the end of the experiment (day 100 of age) or transiently until day 56 of age with the selective AT(1) receptor antagonist candesartan or with the combination of candesartan and the AT(2) receptor antagonist PD 123319. Persistent treatment with candesartan completely prevented the rise in BP, proteinuria and the increase in left ventricular weight/body weight ratio, whereas transient treatment with candesartan was effective only as long as the drug was administered. In the presence of candesartan, PD 123319 was without effect. Our results show that in male heterozygous TGR persistent candesartan treatment completely prevented hypertension and end-organ damage as long as the drug was administered, whereas transient AT(1 )receptor blockade had no long-term effects.
Citace poskytuje Crossref.org